Live Breaking News & Updates on Recent Corporate

Stay updated with breaking news from Recent corporate. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

BioLineRx : Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

. ....

United States , Israel General , Philip Serlin , Twitterand Linkedin , Philipa Serlin , Gloria Biosciences , Moran Meir , John Lacey , Gloria Bioscience , Exchange Commission On , Medicaid Services , Lifesci Advisors , Washington University In St , International Society For Pharmacoeconomics , Outcomes Research On , American Society Of Clinical Oncology , Centers For Medicare , Biolinerx Ltd , Securities Exchange , American Society For Apheresis , Columbia University , Washington University School Of Medicine , Ma Ayan Street , Principal Executive Offices , Quarter Ended March , Securities Act ,

'Psychedelics-Inspired' Meds For Depression, Anxiety, Addiction Producer Trims Q1 Net Loss YoY, Increases Cash On Hand - Enveric Biosciences (NASDAQ:ENVB)

Enveric Biosciences reported on Wednesday financial results for the first quarter of 2024 ended March 31, 2024."We believe the first quarter of 2024 was a highly productive period for Enveric as the company continued to advance the development of the lead neuroplastogen drug candidate, EB-003, in preparation for an investigational new drug (IND) application and the expected initiation of a planned clinical development program," Joseph Tucker, Ph.D., director and CEO of Enveric, said. "EB-003 was designed specifically to address this major safety profile deficiency in the first-generation psychedelic approach to treating neuropsychiatric illness, and we are excited to advance its development." ....

Enveric Biosciences , Joseph Tucker , Product And Business Development , Recent Corporate ,

Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnin

Published Phase 1 data of SON-1010 in Frontiers in Immunology demonstrating the safety and tolerability of the F H AB-derived Interleukin 12 in healthy volunteersAnnounced early safety data from the company's Phase 1b/2a clinical trial of SON-080 in patients with chemotherapy-induced peripheral neuropathy (CIPN)Rece. ....

New Jersey , United States , Pankaj Mohan , Jack Yauch , Jay Cross , Securities Exchange , Sonnet Biotherapeutics Inc , Exchange Commission , Solebury Strategic Communications , Jersey Technology Business Tax Certificate Transfer Program , American Association For Cancer Research , Sonnet Biotherapeutics Holdings Inc , Published Phase , American Association , Cancer Research , Sonnet Founder , Chief Executive , Recent Corporate , Data Safety Monitoring Board , Diabetic Peripheral Neuropathy , Dose Interleukin , Quarter Ended March , Fully Human Albumin Binding , Securities Act , Securities Exchange Act , Private Securities Litigation Reform Act ,

Abeona Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Progress

Abeona Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Progress
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Corporate Communications , Company Biologics License Application , Drug Administration , Exchange Commission , Society For Investigative Dermatology , Abeona Therapeutics Inc , Securities Exchange , Therapeutics Reports First Quarter , Recent Corporate , Vish Seshadri , Chief Executive Officer , Complete Response Letter , Biologics License Application , Chemistry Manufacturing , Investigative Dermatology , Annual Meeting , Quarter Financial Results , Cash Runway , Priority Review Voucher , Entry Code , Securities Act , Securities Exchange Act , Annual Report , Consolidated Statements , Comprehensive Loss , Media Contact ,